Why in news Britain’s drug regulator authorised the Alzheimer’s drug Leqembi , saying it’s the first medicine to show some impact in slow...
Why in news
Britain’s drug regulator authorised the Alzheimer’s drug Leqembi, saying it’s the first medicine to show some impact in slowing the progression of the disease.
Leqembi
Leqembi (Lecanemab) is an antibody intravenous (IV) infusion therapy that targets and removes beta-amyloid from the brain
It is a prescription medicine used to treat people with Alzheimer’s disease.
LEQEMBI can cause serious side effects, including:
ARIA (amyloid-related imaging abnormalities) (see above)
Serious allergic reactions
Infusion-related reactions
COMMENTS